Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Henagliflozin, Retagliptin, and Metformin vs Sequential Therapy in Newly Diagnosed T2DM
NCT06417489Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of henagliflozin and retagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Proportion of subjects with HbA1c < 7% at 12 weeks. Planned start May 2024; status: not yet recruiting.
02
Drugs
henagliflozinretagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06417489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417489.